American International Group, Inc. Athira Pharma, Inc. Transaction History

American International Group, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$2.26 - $4.22 $739 - $1,379	327 Added 2.03%	16,410 $41,000
Q4 2022 Feb 10, 2023	SELL	$2.76 - $3.71 $160 - $215	-58 Reduced 0.36%	16,083 $50,000
Q3 2022 Nov 14, 2022	BUY	$2.93 - $3.96 $668 - $902	228 Added 1.43%	16,141 $48,000
Q2 2022 Aug 12, 2022	SELL	$2.74 - $13.43 $271 - $1,329	-99 Reduced 0.62%	15,913 $49,000
Q1 2022 May 13, 2022	SELL	$8.96 - $13.51 $10,097 - $15,225	-1,127 Reduced 6.58%	16,012 $216,000
Q4 2021 Feb 11, 2022	SELL	$9.17 - $16.39 $4,704 - $8,408	-513 Reduced 2.91%	17,139 $223,000
Q3 2021 Nov 12, 2021	SELL	$9.15 - $11.09 $3,843 - $4,657	-420 Reduced 2.32%	17,652 $166,000
Q2 2021 Aug 13, 2021	BUY	$10.24 - $20.87 $102,225 - $208,345	9,983 Added 123.41%	18,072 $185,000
Q1 2021 May 07, 2021	BUY	$16.9 - $29.77 $10,478 - $18,457	620 Added 8.3%	8,089 $149,000
Q4 2020 Feb 12, 2021	BUY	$16.48 - $34.3 $123,089 - $256,186	7,469 New	7,469 $256,000

16.9M

112K

68K

Ticker ATHA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,817,700
Market Cap $22.3M
Description
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical tri...

Get notified when there are updates to the investment portfolio of American International Group, Inc., based on Form 13F filings with the SEC.

Stay updated on American International Group, Inc. with notifications on news.